Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

BioCentury This Week by BioCentury

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvga...View more